Biomarker · Gene alteration

KRAS G12C

KRAS codon 12 point mutation p.G12C detected by sequencing or PCR in tumor tissue or plasma; used as a predictive marker for KRAS G12C inhibitors in non-small cell lung and colorectal cancer.

CI-BIO-00000015KRAS graph →NCIt C98365

Also calledp.G12C · KRAS G12C-mutated · c.34G>T

Derived

Associated cancers (6)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	7	7	—	—	2 / 2 / 1 / 2 / 0
Lung Non-Small Cell Carcinoma	4	3	1	—	1 / 3 / 0 / 0 / 0
Multiple Myeloma	3	3	—	—	0 / 0 / 0 / 3 / 0
Malignant Lung Neoplasm	2	1	—	1	0 / 2 / 0 / 0 / 0
Malignant Neoplasm

Derived

Drugs with predictive evidence (15)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
MelphalanSmall Molecule	3	—	3	D	0 / 3	Multiple Myeloma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
Cetuximab

Curated evidence

Predictive evidence items (16)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–16 of 16 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12C16
Divarasib

Regulatory

Approvals mentioning the linked drugs (168)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Cetuximab	CA Health Canada	—	Marketed in Canada as ERBITUX (DIN 02271249) under ATC L01FE01 CETUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 28, 2008	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02458020) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 17, 2017	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02439336) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 2, 2016	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02437031) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Oct 29, 2025	Feb 27, 2015	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02412225) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 17, 2018	Mar 28, 2014	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION (DIN 02412233) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 17, 2018	Mar 28, 2014	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION USP (DIN 02361957) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 1, 2011	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177099) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 30, 2018	Dec 31, 1995	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177080) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 31, 2020	Dec 31, 1995	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as PMS-DOCETAXEL (DIN 02436361) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 15, 2023	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02444410) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465655) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02441845) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as PMS-DOCETAXEL (DIN 02436388) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 15, 2023	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465647) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TARO-DOCETAXEL (DIN 02465531) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022	—	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as NAT-ERLOTINIB (DIN 02483939) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Dec 1, 2021	May 8, 2019	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as NAT-ERLOTINIB (DIN 02483920) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Oct 1, 2021	May 8, 2019	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as NAT-ERLOTINIB (DIN 02483912) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince May 1, 2021	May 8, 2019	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as APO-ERLOTINIB (DIN 02461870) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 22, 2017	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as APO-ERLOTINIB (DIN 02461862) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 22, 2017	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as APO-ERLOTINIB (DIN 02461889) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 22, 2017	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as PMS-ERLOTINIB (DIN 02454386) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 31, 2025	Jul 28, 2016	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as PMS-ERLOTINIB (DIN 02454394) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 28, 2016	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TEVA-ERLOTINIB (DIN 02377691) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 8, 2014	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TEVA-ERLOTINIB (DIN 02377705) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 8, 2014	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TEVA-ERLOTINIB (DIN 02377713) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 8, 2014	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TARCEVA (DIN 02269007) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 1, 2024	Jan 5, 2007	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TARCEVA (DIN 02269023) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 1, 2024	Jul 19, 2005	health-canada-dpd
Erlotinib	CA Health Canada	—	Marketed in Canada as TARCEVA (DIN 02269015) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 1, 2024	Jul 19, 2005	health-canada-dpd
Gefitinib	CA Health Canada	—	Marketed in Canada as JAMP GEFITINIB (DIN 02500663) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 23, 2020	health-canada-dpd
Gefitinib	CA Health Canada	—	Marketed in Canada as NAT-GEFITINIB (DIN 02491796) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Mar 1, 2026	Nov 13, 2019	health-canada-dpd
Gefitinib	CA Health Canada	—	Marketed in Canada as SANDOZ GEFITINIB (DIN 02487748) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 31, 2026	Jun 26, 2019	health-canada-dpd
Gefitinib	CA Health Canada	—	Marketed in Canada as APO-GEFITINIB (DIN 02468050) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 18, 2017	health-canada-dpd
Gefitinib	CA Health Canada	—	Marketed in Canada as IRESSA (DIN 02248676) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 17, 2003	health-canada-dpd
Gefitinib	CA Health Canada	—	Marketed in Canada as AURO-GEFITINIB (DIN 02533685) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Gefitinib	CA Health Canada	—	Marketed in Canada as EUGIA-GEFITINIB (DIN 02547546) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Melphalan	CA Health Canada	—	Marketed in Canada as TARO-MELPHALAN (DIN 02480026) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 25, 2021	health-canada-dpd
Melphalan	CA Health Canada	—	Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02468921) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Apr 13, 2023	Nov 20, 2018	health-canada-dpd
Melphalan	CA Health Canada	—	Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02473348) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 18, 2018	health-canada-dpd
Melphalan	CA Health Canada	—	Marketed in Canada as ALKERAN (DIN 02087286) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1995	health-canada-dpd
Melphalan	CA Health Canada	—	Marketed in Canada as ALKERAN (DIN 00004715) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1964	health-canada-dpd
Melphalan	CA Health Canada	—	Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02537389) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Melphalan	CA Health Canada	—	Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02526077) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 29, 2026	—	health-canada-dpd
Melphalan	CA Health Canada	—	Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02508214) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Panitumumab	CA Health Canada	—	Marketed in Canada as VECTIBIX (DIN 02308509) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 3, 2017	health-canada-dpd
Panitumumab	CA Health Canada	—	Marketed in Canada as VECTIBIX (DIN 02308487) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 27, 2008	health-canada-dpd
Panitumumab	CA Health Canada	—	Marketed in Canada as VECTIBIX (DIN 02308495) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO (DIN 02530147) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 3, 2023	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO (DIN 02530139) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 3, 2023	health-canada-dpd

Associated cancers (6)

Drugs with predictive evidence (15)

Predictive evidence items (16)

Approvals mentioning the linked drugs (168)

Active trials (279)

Linked publications (17)